Anaptys Bio Reports Continued Jemperli Sales Growth
News related to:AnaptysBio, Inc · 3 min read
SAN DIEGO, Sept. 21, 2026 /CourierPR/ -- Anaptys Bio, Inc., a company focused on managing financial collaborations for Jemperli with GSK, has reported its second quarter and transitional fiscal year 2026 financial results, which include significant growth in Jemperli's global net sales. For the six months ended June 30, 2026, Jemperli achieved global net sales of $644 million (£480 million), marking a 34% year-over-year increase. This growth is attributed to robust sales performance both domestically and internationally.
In addition to the strong sales figures, Anaptys Bio also highlighted positive interim results from the pivotal AZUR-1 trial of Jemperli in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. These results, announced in July, demonstrated a meaningful and sustained clinical complete response rate for 12 months (cCR12) with no detectable signs of cancer for at least one year. The FDA has assigned a PDUFA action date of February 2027, with eligibility for expedited review through the National Priority Voucher program, which could result in an earlier FDA decision. The company anticipates that Jemperli could be approved in monotherapy for dMMR/MSI-H neoadjuvant rectal cancer by the end of 2027.
Anaptys Bio also provided an update on its ongoing litigation with GSK and Tesaro. The trial held in July resulted in a post-trial hearing scheduled for October 20, 2026, with a judgement anticipated in Q4 2026 or Q1 2027. The company is seeking reversion of Jemperli rights as a remedy, and it anticipates a judgement in Q4 2026 or Q1 2027.
In terms of Jemperli's financial performance, GSK reported strong commercial performance for the quarter, with global net sales of $331 million (£248 million), representing a 26% year-over-year growth. Anaptys Bio continues to expect to achieve annualized Jemperli royalties of over $390 million by 2029, at GSK's peak monotherapy sales guidance of over $2.7 billion. The company estimates that Sagard will have accrued approximately $301 million in royalties and sales milestones through the second quarter of 2026, with the remaining $299 million non-recourse debt monetization expected to be paid down in the second half of 2027.
Anaptys Bio has also announced that its fiscal year-end will be changed from December 31 to June 30, beginning with the quarter ending September 30, 2026. As of June 30, 2026, the company has not repurchased any shares under its $100 million Stock Repurchase Plan, which will expire on December 31, 2026, and may be suspended or discontinued at any time. The company's cash, cash equivalents, and investments decreased by $47.5 million to $164.1 million as of June 30, 2026, due to $72.9 million in operating activities offset by $25.4 million in revenue from stock option exercises.
In the meantime, Anaptys Bio's collaboration revenue increased from $22.3 million in the three months ended June 30, 2025, to $27.5 million in the three months ended June 30, 2026, and from $50.0 million in the six months ended June 30, 2025, to $53.0 million in the six months ended June 30, 2026. This increase is primarily due to a 25% and 34% rise in Jemperli royalties for the three and six months ended June 30, 2026, offset by $9.7 million in revenue recognized for the Vanda license agreement for the three months and six months ended June 30, 2025.
Anaptys Bio's general and administrative expenses increased from $4.0 million in the three months ended June 30, 2025, to $16.0 million in the three months ended June 30, 2026, and from $8.3 million in the six months ended June 30, 2025, to $23.4 million in the six months ended June 30, 2026. The increase was primarily due to legal costs related to the separation of the company and the ongoing litigation with GSK and Tesaro, as well as non-cash stock compensation.
Research and development expenses from continuing operations were negative $2.7 million for the six months ended June 30, 2026, compared to negative $1.7 million for the six months ended June 30, 2025. The negative balance for the six months ended June 30, 2026, was primarily due to adjustments related to the closeout of clinical contracts reducing expenses incurred prior to the separation.
In terms of income taxes, Anaptys Bio reported a benefit for income taxes from continuing operations of $181.5 million for the six months ended June 30, 2026.